Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) Operating Expenses: 2022-2024

Historic Operating Expenses for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to $163.8 million.

  • Entrada Therapeutics' Operating Expenses rose 18.04% to $48.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $183.1 million, marking a year-over-year increase of 16.28%. This contributed to the annual value of $163.8 million for FY2024, which is 23.90% up from last year.
  • Latest data reveals that Entrada Therapeutics reported Operating Expenses of $163.8 million as of FY2024, which was up 23.90% from $132.2 million recorded in FY2023.
  • Entrada Therapeutics' Operating Expenses' 5-year high stood at $163.8 million during FY2024, with a 5-year trough of $97.2 million in FY2022.
  • Moreover, its 3-year median value for Operating Expenses was $132.2 million (2023), whereas its average is $131.1 million.
  • Data for Entrada Therapeutics' Operating Expenses shows a peak YoY spiked of 35.92% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Entrada Therapeutics' Operating Expenses stood at $97.2 million in 2022, then soared by 35.92% to $132.2 million in 2023, then grew by 23.90% to $163.8 million in 2024.